Herve Hoppenot - Apr 1, 2025 Form 4 Insider Report for INCYTE CORP (INCY)

Role: Chairman / CEO, Director, President
Signature: /s/ Elizabeth Feeney, Attorney-In-Fact
Stock symbol: INCY
Transactions as of: Apr 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/3/2025, 04:49 PM
Previous filing: Jan 22, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INCY	Common Stock	Award	$0	+66.9K	+13.47%	$0.00	564K	Apr 1, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.
F2	This includes an aggregate of 181,595 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

Content

Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

This includes an aggregate of 181,595 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.